Viatris (Nasdaq: VTRS) has submitted a New Drug Application (NDA) to the US FDA for MR-107A-02 (fast-acting meloxicam), an investigational oral reformulation of the NSAID meloxicam, seeking approval for the treatment of moderate-to-severe acute pain in adults. The FDA has accepted the application for review and assigned a PDUFA goal date of December 27, 2026.
The NDA was filed under the 505(b)(2) regulatory pathway, which permits applicants to rely in part on existing safety and efficacy data for a previously approved compound. In this case, meloxicam is a well-characterized NSAID; the novelty of MR-107A-02 lies in its formulation, which Viatris says was engineered to accelerate dissolution and absorption relative to currently marketed oral meloxicam products. The company has not disclosed a proposed brand name. No priority review designation was mentioned in the company's announcement.
Clinical evidence supporting the application
The NDA is supported by data from two randomized, double-blind, placebo-controlled Phase III trials conducted in post-surgical acute pain models. The herniorrhaphy trial (NCT06215859) enrolled 579 subjects, and the bunionectomy trial (NCT06215820) enrolled 410 subjects. Both studies included an active comparator arm using tramadol 50 mg every six hours to confirm pain model sensitivity, alongside placebo and MR-107A-02 arms.
The primary endpoint in both trials was the Sum of Pain Intensity Difference over 0–48 hours (SPID 0–48h), measured using the Numeric Rating Scale. Viatris reported that MR-107A-02 met the primary endpoint in both studies. In the herniorrhaphy trial, the least-squares mean difference in SPID 0–48h versus placebo was 50.1 (95% CI: 35.4–64.8; p<0.001). In the bunionectomy trial, the corresponding figure was 82.7 (95% CI: 62.0–103.4; p<0.001). Secondary endpoints included opioid rescue medication use; the company said 72.6% of MR-107A-02-treated patients in the herniorrhaphy study were opioid-free versus 58.6% in the placebo arm (p=0.002), and 56.9% versus 33.1% in the bunionectomy study (p<0.001). Viatris said adverse events were consistent with the established NSAID class profile. Top-line results were presented at PAINWeek 2025.
Scientific and competitive context
The NDA enters a space that has seen renewed activity following the January 2025 US FDA approval of Journavx (suzetrigine), developed by Vertex Pharmaceuticals (Nasdaq: VRTX, Cambridge, Massachusetts). Suzetrigine is a selective NaV1.8 sodium channel inhibitor — a first-in-class mechanism that blocks peripheral pain signal transmission without central nervous system activity or opioid receptor engagement. Its approval was the first for a new non-opioid mechanism in acute pain in over two decades.
MR-107A-02 operates through a different and more familiar mechanism. Meloxicam is a COX-2-preferential NSAID that inhibits prostaglandin synthesis; the compound's anti-inflammatory and analgesic properties are well understood from years of use in chronic pain indications. The formulation strategy behind MR-107A-02 addresses a recognized pharmacokinetic limitation of conventional oral meloxicam, which reaches peak plasma concentration approximately five to six hours after dosing — too slow for acute pain management. Accelerating absorption is the central clinical rationale for the reformulation.